在性结肠炎中,通过阻断NLRP3炎症酶介导的热灭症来保护TRPM7的保护作用
Jinzhen Peng1, Shuai Tang1, Lifang Huang2
1Department of gastroenterology, Shaoguan First People's Hospital, Shaoguan 512000, PR China.
Prostaglandins & other lipid mediators
|September 11, 2024
概括
向TRPM7 (过时受体潜力美拉斯7) 显示了性结肠炎 (UC) 的治疗潜力. 减少TRPM7可以通过抑制NLRP3依赖性热灭酶来缓解炎症和肠道屏障损伤.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 暂时受体潜能拉斯7 (TRPM7) 呈现离子通道和激酶功能,使其成为免疫调节的潜在目标.
- 性结肠炎 (UC) 是一种具有复杂潜在机制的慢性炎症性肠病.
研究的目的:
- 研究TRPM7在性结肠炎 (UC) 病变发生过程中的作用.
- 阐明TRPM7影响UC进展的分子机制.
主要方法:
- 使用DSS刺激建立了UC的体内小鼠和体内细胞模型.
- 通过RT-qPCR和西式涂抹评估TRPM7表达.
- 通过各种测试 (H&E,DAI,MPO,ELISA,FITC-dextran流量,TEER) 评估结肠损伤,炎症,氧化应激和肠道屏障功能.
- 通过免疫光和西式涂抹,研究了NLRP3依赖性烧灭.
主要成果:
- 在体外和体外UC模型中,TRPM7枯竭显著降低了炎症,氧化损伤和肠壁功能障碍.
- 沉默TRPM7抑制了NLRP3炎症酶介导的烧灭.
- 服用NLRP3激动剂部分逆转了TRPM7沉默的保护作用.
结论:
- TRPM7在UC发展中起着至关重要的作用.
- 通过抑制NLRP3依赖性烧灭,TRPM7的删除表明了UC的治疗潜力.
- 向TRPM7可能为治疗性结肠炎提供一种新的治疗策略.
相关概念视频
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
T Cell Types and Functions
961
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
961
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
358
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


